Antidepressant Interactions of Ketamine and Glycogen Synthase Kinase-3 (GSK3) in Mice

摘要: of a thesis at the University Miami. Thesis supervised by Dr. Eleonore Beurel No. pages in text. (58) Depression is prevalent and debilitating mood disorder afflicting nearly one five people United States. Current medications used for treatment depression are inadequate because they have delayed onset therapeutic benefit, low efficacy, several side effects, require chronic administration. This presents need improved antidepressant therapies. Ketamine, general anesthetic, was recently shown to rapid-acting effects sub-anesthetic dose. It unknown how ketamine elicits an effect, but mechanisms been proposed, including glycogen synthase kinase-3 (GSK3) inhibition α-amino-3-hydroxy-5-methylospxazol-4-propionic acid (AMPA) receptor activation. focuses on role GSK3 effect expanding previous findings additional depressive-like behavior models mice examines molecular AMPA receptors response order further understand signaling that leads ketamine’s effect. I provide evidence requires activation support mechanism involving interaction between trafficking ketamine. will possible strategies develop much needed new